|
| | Tolterodine tartrate Basic information |
| | Tolterodine tartrate Chemical Properties |
| Melting point | 205-210°C | | alpha | 54625 +36.0° | | storage temp. | Sealed in dry,2-8°C | | solubility | Methanol (Sparingly), Water (Slightly) | | form | Solid | | pka | 9.87(at 25℃) | | color | White to Off-White | | BCS Class | 1 | | CAS DataBase Reference | 124937-52-6(CAS DataBase Reference) |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-37/39 | | RIDADR | UN 2811 6.1 / PGIII | | HS Code | 29222990 | | Toxicity | LD50 i.v. in male mice: 10-20 mg/kg (Jnsson) |
| | Tolterodine tartrate Usage And Synthesis |
| Chemical Properties | White-to-Off-White Crystalline Powder | | Originator | Detrol,Pharmacia and Upjohn | | Uses | Tolterodine tartrate (Detrol LA) is a tartrate salt of tolterodine that is a competitive muscarinic receptor antagonist. Tolterodine tartrate (Detrol LA) is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urge | | Uses | Tolterodine (tartrate) is a competitive antagonist of muscarinic (M) receptors (Ki = 1.4, 2.7, 3.6, 3.1, and 2.2 nM for M1 through M5, respectively). Antagonists of muscarinic receptors, including tolterodine, are effective in treating overactive bladder symptoms.[Cayman Chemical] | | Uses | A muscarinic receptor antagonist. Used in the treatment of urinary incontinence. | | Manufacturing Process | Trans-cinnamic acid (100 g, 675 mmol) is added to a 1 L 4-neck round bottom
flask equipped with a mechanical stirrer, thermocouple, and nitrogen inlet.
Para-cresol (76.6 g, 708 mmol) is preheated in a water bath at 60°C and
added to the cinnamic acid followed by concentrated sulfuric acid (13.0 ml,
243 mmol). The reaction is immediately heated to a set point of 122.5°C and
stirred at 120°-125°C until judged to be complete by HPLC analysis. When the
reaction is complete the mixture is cooled to 100°C and added to a
prewarmed separatory funnel (500 ml). The bottom layer containing the
sulfuric acid is removed and toluene (280 ml), water (50 ml) and potassium
carbonate (47%, 10 ml) are added to the separatory funnel containing the
crude product. The pH of the aqueous layer is adjusted to between 5-8 with
additional 47% potassium carbonate. The layers are separated and the
organic layer is then washed once with water (50 ml). The organic layer is
concentrated to a final volume of approximately 150 ml under reduced
pressure. Isopropanol (350 ml) is then added, and distillation is continued to
a volume of 350 ml. Isopropanol (150 ml) is again added and again distilled
to 350 ml (2 times). The mixture is then cooled to 30°-40°C with rapid
stirring until the product crystallizes. The rapid stirring is continued after
crystallization. The product is cooled to 0°-5°C and held at this temperature
for 1 h, filtered and washed with isopropanol (200 ml) cooled to 0°-5°C. If the
last portion of the wash is colored the wash is continued until no more color is
removed. The solids are then dried at 60°C under reduced pressure to give
the 3,4-dihydro-6-methyl-4-phenyl-2H-benzopyran-2-one, melting point
(uncorrected) 83°-85°C.
3,4-Dihydro-6-methyl-4-phenyl-2H-benzopyran-2-one (100.0 g, 420.2 mmol)
is added to toluene (500 ml). The mixture is degassed by purging alternately
with vacuum and nitrogen and then cooled to -21°C. Diisobutylaluminum
hydride in toluene solution (DIBAL, 1.5 M, 290 ml, 435 mmol) is then slowly
added over 2 h via add funnel while maintaining the reaction temperature at -
20°-25°C. The reaction is usually done when the DIBAL add is completed. If the reaction is not done additional DIBAL can be added in increments. When
the reaction is done (<1% lactone) ethyl acetate (45 ml) is added at -20°-
25°C via add funnel. Very little exotherm is observed. Next, citric acid (23%,
500 ml) is added. The mixture is stirred at 45°-50°C for 1 h (or stirred
overnight at 20°-25°C), the phases are separated, the organic phase is
washed with water (2 times 300 ml). The organic phase is concentrated to
250 ml under reduced pressure. Methanol (500 ml) is added, and the mixture
is concentrated to 250 ml. The methanol addition and distillation is repeated
to give the 3,4-dihydro-6-methyl-4-phenyl-2H-benzopyran-2-ol in methanol
solution.
3,4-Dihydro-6-methyl-4-phenyl-2H-benzopyran-2-ol in methanol (500 ml) is
slowly added to palladium on carbon (5%, 22 g, 1.5 mmol) while maintaining
a slight nitrogen purge. If 3,4-dihydro-6-methyl-4-phenyl-2H-benzopyran-2-ol
is added too quickly without a nitrogen purge the catalyst will ignite the
methanol. Diisopropylamine (147.0 ml, 1.05 mol) is added, and the mixture is
hydrogenated at 45-50 psi and 48°C until the reaction is judged to be
complete by HPLC (<2% lactol). The reaction is usually done after 10 h, but
can be run overnight. The reaction mixture is cooled and removed from the
hydrogenator using a methanol (150 ml) rinse. The combined reaction mixture
and rinse is filtered through a bed of solka floc (10 g). The solka floc is
washed thoroughly with methanol (100 ml) and the filtrate is concentrated to
remove methanol while ethyl acetate is being added back. The volume of this
solution of the (2-diisopropylamino)ethyl)benzyl)-p-cresol is adjusted to 700
ml using ethyl acetate and the mixture is heated to 55°C.
To form the hydrochloride salt of the (2-diisopropylamino)ethyl)benzyl)-p_x0002_cresol (Tolterodine), concentrated hydrochloric acid (52.5 ml, 630 mmol) is
added over 15 min. The resulting slurry is gradually cooled to -15°-20°C and
held at this temperature for 1 h. Tolterodine hydrochloride is collected by
filtration, washed 3 times with ethyl acetate, and dried overnight under
reduced pressure at 600 to give the tolterodine hydrochloride, melting point
199°-201°C.
Tolterodine hydrochloride (130.0 g, 359 mmol), methylene chloride (1.3 L)
and water (650 ml) are mixed. The mixture is stirred rapidly while adding
sodium hydroxide (50%, 13.0 ml) and sodium carbonate (13.0 g, 123 mmol).
The pH as determined by pH paper is 10-11. After stirring thoroughly for
approximately 15 min two clear homogeneous phases form. Stirring is
continued for another 45 min, the layers are separated and the organic phase
is washed with water (2 times 650 ml). The methylene chloride mixture is
concentrated under reduced pressure. The concentrate is dissolved in ethanol
(325 ml) and warmed to 60°-70°C. L-tartaric acid (80.84 g, 539 mmol)
slurried in hot ethanol (810 ml) is added via add funnel at 60°-70°C over
approximately 30 min. When the addition is done the slurry is refluxed for 1
h, gradually cooled to 0°C and held at this temperature for 1 h. The slurry is
filtered, washed with ethanol (2 times 260 ml) previously cooled to 0°C, and
dried overnight under reduced pressure at 60°C to give the crude title
compound. The crude product (136.0 g) and ethanol (5.44 L) are mixed and
heated to 80°C for 30 min. The mixture is concentrated to half the initial
volume by distilling 2.72 L of ethanol. The mixture is gradually cooled to 20°-
25°C over 1 h, placed in an ice bath, and held at 0°C for 1 h. The tolterodine
L-tartrate is collected by filtration, washed with ethanol (2 times 272 ml )
previously cooled to 0°C, and dried overnight under reduced pressure at 60°C to give product. This procedure was repeated a second time on 81.0 g of once
recrystallized tolterodine L-tartrate to give the optically active (+)-(R)-2-(α-
(2-(diisopropylamino)ethyl)benzyl)-p-cresol L-tartrate, melting point
(uncorrected)=210°-211°C. | | Therapeutic Function | Anticholinergic | | General Description | Tolterodine Tartrate is a tertiary muscarinic?antagonist, basically used to manage urinary frequency, urgency, and incontinence in detrusor instability. | | Biological Activity | tolterodine tartrate (detrol la) is a tartrate salt of tolterodine that is a competitive muscarinic receptor antagonist. | | Clinical Use | Selective vasopressin V2 -receptor antagonist:
Treatment of hyponatraemia secondary to SIADH
To slow the progression of autosomal dominant polycystic kidney disease (ADPKD) | | Drug interactions | Potentially hazardous interactions with other drugs
Anti-arrhythmics: increased risk of ventricular
arrhythmias with amiodarone, disopyramide and
flecainide; increased risk of antimuscarinic side
effects with disopyramide.
Antifungals: avoid concomitant use with itraconazole
and ketoconazole.
Antivirals: avoid concomitant use with
fosamprenavir, indinavir, lopinavir, ritonavir and
saquinavir.
Beta-blockers: increased risk of ventricular
arrhythmias with sotalol. | | Metabolism | Metabolised mainly by the cytochrome P450 isoenzyme CYP3A4. Eliminated mainly by the faecal route |
| | Tolterodine tartrate Preparation Products And Raw materials |
|
